We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

6 hedge funds and large institutions have $4.51M invested in Hepion Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 3 → 6 (+3)

48% less capital invested

Capital invested by funds: $8.61M → $4.51M (-$4.1M)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$1.99M
2
Barclays
Barclays
United Kingdom
+$497K
3
Morgan Stanley
Morgan Stanley
New York
+$497K

Top Sellers

Rank Fund Capital Flow
1
RA
RFG Advisory
Alabama
-$65K
2
BRWA
B. Riley Wealth Advisors
Florida
-$46K
3
Citadel Advisors
Citadel Advisors
Florida
-$46K
4
VKH
Virtu KCG Holdings
New York
-$30K
5
AIM
Acrospire Investment Management
Illinois
-$29K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.4M – – –
AFM
2
Anson Funds Management
Texas
$1.39M +$1.99M +4 New
HighTower Advisors
3
HighTower Advisors
Illinois
$608K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$201K – – –
Morgan Stanley
5
Morgan Stanley
New York
$172K +$497K +1 New
Barclays
6
Barclays
United Kingdom
$170K +$497K +1 New
JP Morgan Chase
7
JP Morgan Chase
New York
$116K – – –
PFS
8
Prospera Financial Services
Texas
$99K – – –
CS
9
Credit Suisse
Switzerland
$87K – – –
Northern Trust
10
Northern Trust
Illinois
$63K – – –
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
$46K – – –
BlackRock
12
BlackRock
New York
$32K – – –
TSS
13
Two Sigma Securities
New York
$30K – – –
Bank of New York Mellon
14
Bank of New York Mellon
New York
$20K – – –
UBS Group
15
UBS Group
Switzerland
$17K – – –
ISL
16
Ingalls & Snyder LLC
New York
$12K – – –
BWA
17
BDO Wealth Advisors
Florida
$10K – – –
Cambridge Investment Research Advisors
18
Cambridge Investment Research Advisors
Iowa
$9K – – –
LPL Financial
19
LPL Financial
California
$9K – – –
FFA
20
First Foundation Advisors
California
$6K – – –
MCIA
21
Mountain Capital Investment Advisors
Colorado
$3K – – –
Wells Fargo
22
Wells Fargo
California
$2K – – –
Creative Planning
23
Creative Planning
Kansas
$1K – – –
DADC
24
D.A. Davidson & Co
Montana
$1K – – –
VIA
25
Vantage Investment Advisors
Pennsylvania
$1K – – –
1
2

HEPA Hedge Fund Activity: Q2 2017 in Review

6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2017, worth a combined $4.51M — down 48% from $8.61M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new HEPA positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.99M. The largest seller was RFG Advisory, cutting an estimated $65K.

  • 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2017, up from 3 in Q1 2017.
  • Funds reported $4.51M of Hepion Pharmaceuticals stock for Q2 2017, down 48% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q2 2017 and 0 closed out, a net change of +3 holders.
  • The largest Hepion Pharmaceuticals buyer in Q2 2017 was Anson Funds Management, an estimated $1.99M added.
  • The largest Hepion Pharmaceuticals seller in Q2 2017 was RFG Advisory, an estimated $65K sold.

Based on aggregated 13F filings for Q2 2017.